Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris’ commitment to the primary periodic paralysis community and the...
Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock
Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution...
Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million ...
Barchart Research What to Expect from XERS Earnings XERS Generated May 6, 2026 Current Price $6.37 EPS Estimate $$0.00 Consensus Rating Strong Buy Average Move 8.02% Xeris Biopharma's Recorlev Momentum...
Conference Call to be Held at 8:30 a.m. ET
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million ...